基因组时代的临床药理学和药物遗传学：DMET 平台。
Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.
机构信息
National Cancer Institute, Bethesda, MD 20892, USA.
出版信息
Pharmacogenomics. 2010 Jan;11(1):89-103. doi: 10.2217/pgs.09.154.
Abstract
While no genome-wide pharmacogenetics study has yet been published, the field of pharmacogenetics is moving towards exploratory, large-scale analyses of the interaction between genetic variation and drug treatment. The Drug Metabolizing Enzymes and Transporters (DMET) platform offers a standardized set of 1936 variants in 225 genes related to drug absorption, distribution, metabolism and elimination that is useful to scan the genome for previously unknown associations between variation in absorption, distribution, metabolism and elimination genes and pharmacokinetic and pharmacodynamic outcomes of drug treatment. The purpose of this review is to put the DMET platform into context within the current study designs that have been used in pharmacogenetics, and to explore the role that DMET has played - and will play - in future pharmacogenetics studies.
摘要
虽然尚未发表全基因组药物遗传学研究，但药物遗传学领域正朝着探索性、大规模分析遗传变异与药物治疗之间相互作用的方向发展。药物代谢酶和转运体（DMET）平台提供了一套标准化的 1936 个变体，涉及与药物吸收、分布、代谢和消除相关的 225 个基因，这对于扫描基因组中吸收、分布、代谢和消除基因的变异与药物治疗的药代动力学和药效学结果之间以前未知的关联非常有用。本文的目的是将 DMET 平台置于当前药物遗传学研究设计的背景下，并探讨 DMET 在过去和未来药物遗传学研究中所扮演的角色。
相似文献
1
Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.基因组时代的临床药理学和药物遗传学：DMET 平台。
Pharmacogenomics. 2010 Jan;11(1):89-103. doi: 10.2217/pgs.09.154.
2
DMET microarray technology for pharmacogenomics-based personalized medicine.用于基于药物基因组学的个性化医疗的DMET微阵列技术。
Methods Mol Biol. 2010;632:99-124. doi: 10.1007/978-1-60761-663-4_7.
3
DMET-analyzer: automatic analysis of Affymetrix DMET data.DMET 分析器：Affymetrix DMET 数据的自动分析。
BMC Bioinformatics. 2012 Oct 5;13:258. doi: 10.1186/1471-2105-13-258.
4
DMET-Miner: Efficient discovery of association rules from pharmacogenomic data.DMET-Miner：从药物基因组学数据中高效发现关联规则
J Biomed Inform. 2015 Aug;56:273-83. doi: 10.1016/j.jbi.2015.06.005. Epub 2015 Jun 16.
5
Korean, Japanese, and Chinese populations featured similar genes encoding drug-metabolizing enzymes and transporters: a DMET Plus microarray assessment.韩国、日本和中国人群具有编码药物代谢酶和转运蛋白的相似基因：一项DMET Plus微阵列评估。
Pharmacogenet Genomics. 2014 Oct;24(10):477-85. doi: 10.1097/FPC.0000000000000075.
6
Pharmacogenomics of membrane transporters: past, present and future.膜转运体的药物基因组学：过去、现在和未来。
Pharmacogenomics. 2010 Apr;11(4):475-9. doi: 10.2217/pgs.10.22.
7
Gene expression variability in human hepatic drug metabolizing enzymes and transporters.人类肝药物代谢酶和转运体的基因表达变异性。
PLoS One. 2013 Apr 23;8(4):e60368. doi: 10.1371/journal.pone.0060368. Print 2013.
8
Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.炎症是药物代谢酶和转运体的主要调节剂：对药物治疗个体化的影响。
Pharmacol Ther. 2020 Nov;215:107627. doi: 10.1016/j.pharmthera.2020.107627. Epub 2020 Jul 11.
9
Epigenetic techniques in pharmacogenetics.药物遗传学中的表观遗传技术。
Methods Mol Biol. 2013;1015:179-88. doi: 10.1007/978-1-62703-435-7_11.
10
Leading the Way: Multi-Drug Resistance Protein (MDR1) and Clinical Pharmacology-Commentary on Kim et al.引领之路：多药耐药蛋白（MDR1）与临床药理学——对Kim等人研究的评论
Clin Pharmacol Ther. 2025 Jun;117(6):1562-1576. doi: 10.1002/cpt.3675.
引用本文的文献
1
Different perspectives on translational genomics in personalized medicine.个性化医疗中转化基因组学的不同观点。
J Turk Ger Gynecol Assoc. 2022 Dec 8;23(4):314-321. doi: 10.4274/jtgga.galenos.2022.2021-11-4.
2
A resource for integrated genomic analysis of the human liver.人类肝脏综合基因组分析资源
Sci Rep. 2022 Sep 7;12(1):15151. doi: 10.1038/s41598-022-18506-z.
3
Association of Drug-Metabolizing Enzyme and Transporter Gene Polymorphisms and Lipid-Lowering Response to Statins in Thai Patients with Dyslipidemia.泰国血脂异常患者中药物代谢酶和转运体基因多态性与他汀类药物降脂反应的关联
Pharmgenomics Pers Med. 2022 Feb 17;15:119-130. doi: 10.2147/PGPM.S346093. eCollection 2022.
4
Pharmacogenetics of Drugs Used in the Treatment of Cancers.药物治疗癌症中的药物遗传学。
Genes (Basel). 2022 Feb 7;13(2):311. doi: 10.3390/genes13020311.
5
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.使用DMET™平台对韩国人群中重要药物代谢基因进行综合分析。
Transl Clin Pharmacol. 2021 Sep;29(3):135-149. doi: 10.12793/tcp.2021.29.e14. Epub 2021 Sep 2.
6
Assessment of the clinical utility of pharmacogenetic guidance in a comprehensive medication management service.在综合药物管理服务中评估药物遗传学指导的临床效用。
J Am Coll Clin Pharm. 2020 Sep;3(6):1028-1037. doi: 10.1002/jac5.1250. Epub 2020 May 2.
7
Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.人群药代动力学和遗传药理学分析在肾上腺皮质癌患者中的米托坦：朝着个体化剂量迈进。
Clin Pharmacokinet. 2021 Jan;60(1):89-102. doi: 10.1007/s40262-020-00913-y.
8
Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer.肺癌异质人群中紫杉醇药物遗传学研究结果的可重复性。
PLoS One. 2019 Feb 28;14(2):e0212097. doi: 10.1371/journal.pone.0212097. eCollection 2019.
9
The Diversity of REcent and Ancient huMan (DREAM): A New Microarray for Genetic Anthropology and Genealogy, Forensics, and Personalized Medicine.近期和远古人类多样性研究（DREAM）：一个新的基因人类学和遗传学、法医学及个性化医疗的基因芯片。
Genome Biol Evol. 2017 Dec 1;9(12):3225-3237. doi: 10.1093/gbe/evx237.
10
Minimum information required for a DMET experiment reporting.药物代谢酶和转运体基因多态性检测（DMET）实验报告所需的最低信息。
Pharmacogenomics. 2016 Sep;17(14):1533-45. doi: 10.2217/pgs-2016-0015. Epub 2016 Aug 22.
本文引用的文献
1
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.采用 DMET 基因分型平台对接受多西他赛和沙利度胺治疗的去势抵抗性前列腺癌患者进行的药物基因组学研究。
Pharmacogenomics J. 2010 Jun;10(3):191-9. doi: 10.1038/tpj.2009.57. Epub 2009 Dec 29.
2
Genetic ancestry modifies pharmacogenetic gene-gene interaction for asthma.遗传血统会改变哮喘的药物遗传学基因-基因相互作用。
Pharmacogenet Genomics. 2009 Jul;19(7):489-96. doi: 10.1097/FPC.0b013e32832c440e.
3
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.HLA - B*5701基因型是氟氯西林所致药物性肝损伤的主要决定因素。
Nat Genet. 2009 Jul;41(7):816-9. doi: 10.1038/ng.379. Epub 2009 May 31.
4
The Affymetrix DMET platform and pharmacogenetics in drug development.Affymetrix公司的药物代谢酶基因分型检测平台（DMET）与药物研发中的药物遗传学
Curr Opin Mol Ther. 2009 Jun;11(3):260-8.
5
In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions.关于有机阴离子转运多肽（OATP）和有机阳离子转运体（OCT）摄取转运蛋白在药物相互作用中作用的体外证据。
Expert Opin Drug Metab Toxicol. 2009 May;5(5):489-500. doi: 10.1517/17425250902911463.
6
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.细胞色素P450 4F2基因变体（rs2108622）显著影响意大利人群对华法林剂量的个体差异。
Pharmacogenomics. 2009 Feb;10(2):261-6. doi: 10.2217/14622416.10.2.261.
7
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.癌症患者关键药物个体化给药中的药物基因组学进展。
Nat Clin Pract Oncol. 2009 Mar;6(3):153-62. doi: 10.1038/ncponc1303. Epub 2009 Jan 27.
8
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.端粒酶逆转录酶（TERT）-跨膜蛋白1样蛋白（CLPTM1L）基因座处的序列变异与多种癌症类型相关。
Nat Genet. 2009 Feb;41(2):221-7. doi: 10.1038/ng.296. Epub 2009 Jan 18.
9
Gene-environment interactions in asthma.哮喘中的基因-环境相互作用
J Allergy Clin Immunol. 2009 Jan;123(1):3-11; quiz 12-3. doi: 10.1016/j.jaci.2008.10.046.
10
Cytochrome p-450 polymorphisms and response to clopidogrel.细胞色素P-450基因多态性与氯吡格雷的反应
N Engl J Med. 2009 Jan 22;360(4):354-62. doi: 10.1056/NEJMoa0809171. Epub 2008 Dec 22.
Zotero 插件